Ciphergen Biosystems(CIPH): Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH):

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (197)	2/3/2004 10:50:40 AM
From: tom pope	Read Replies (1) of 510

Briefing: 10:09 ET CIPH diagnostic test superior -- Pac Growth 10.59 +0.03: Pacific Growth issues a report on Ciphergen Biosystems, a company on which it initiated coverage two weeks ago, in response to an article in today's NY Times today that details efforts to discover effective biomarkers for early diagnosis of ovarian cancer. The article focuses on Correlogic, a privately held co whose OvaCheck test uses mass spec produced protein patterns (or molecular finger prints) "called" by a computer to diagnose ovarian cancer. While early data appeared promising, further development has proved difficult. Ciphergen is developing its own ovarian cancer diagnostic call Ova-Sure. The firm looks for Ciphergen to publish data and enter into a commercialization partnership for Ova-Sure in the second half of the year. The firm believes Ciphergen's strategy of discovering and validating panels of biomarkers to be a more effective and clinically acceptable route for the development of next generation diagnostics.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next